-

Amalgam Rxand Novo Nordisk® Plan Global Expansion

Insulin Titration App, Dose Check®, to Reach Patients Worldwide

WILMINGTON, Del.--(BUSINESS WIRE)--Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing global expansion of its insulin titration solution with Novo Nordisk. Initially, the companies successfully commercialized Dose Check, a white-labeled version of iSage RxTM, in select countries in South America. Now, with Amalgam’s recently received CE Mark for iSage Rx and Dose Check, Novo Nordisk is planning a global expansion. In 2021, Dose Check will launch in multiple countries in Europe and Asia.

“We’re excited about expanding our partnership with Amalgam and bolstering our efforts to facilitate evidence-based insulin initiation and titration in conjunction with our strong insulin portfolio,” said Anne Dorothee Vonmoos, Novo Nordisk’s senior director, head of commercial planning in io-so commercial affairs and strategy.

“The Dose Check application has been well received by patients and healthcare providers in South America and the launch data is impressive. We have a tremendous opportunity to support patients and healthcare providers across the globe,” said Richard Miklauzic, director for commercial information technology international operations.

“The Dose Check program is evidence of Amalgam’s unique capabilities to support life sciences companies from R&D to commercialization. Amalgam now has software as a medical device (SaMD) solutions cleared on three continents. We look forward to expanding the Dose Check program and supporting Novo Nordisk on a global basis,” said Ryan Sysko, chief executive officer and founder of Amalgam Rx.

About Amalgam Rx

Amalgam Rx is the leader in bringing providers, life sciences, and digital solutions together. For more than 15 years, our team has been reimagining care delivery and creating lasting change across the chronic care ecosystem. Working in partnership with many of the world’s leading life sciences companies and health systems, Amalgam Rx has built an innovative platform for rapidly developing and scaling digital solutions — delivered through a wide variety of business models. Our proven end-to-end methodology enables the entire life cycle from R&D to commercialization. Amalgam’s solutions have generated more than 7 billion RWE data points utilized by patients and providers on three continents. Amalgam is the manufacturer of the iSage Rx app and white-labeled variants, the first prescription-only mobile application for the automated titration of all brands of basal insulin to receive market authorization in the United States, EU, and Brazil. iSage Rx allows physicians to choose from multiple clinically-validated basal insulin algorithms and to tailor the algorithms to the specific needs of their type 2 diabetes patients. For more information on how Amalgam Rx’s regulated, clinically validated technologies bring patients and providers closer together, reduce costs for payers, and unlock sustained value for partners, visit amalgamrx.com.

Contacts

Fred Galik
Phone: 917.331.8248
Email: fgalik@amalgamrx.com

Amalgam Rx


Release Summary
Amalgam Rx, Inc. is announcing global expansion of its insulin titration solution with Novo Nordisk.
Release Versions

Contacts

Fred Galik
Phone: 917.331.8248
Email: fgalik@amalgamrx.com

Social Media Profiles
More News From Amalgam Rx

CVS Health Ventures Makes Strategic Investment in Amalgam Rx

WILMINGTON, Del.--(BUSINESS WIRE)--Amalgam Rx, Inc., a leader in enabling data-driven health care decision making, announced the participation of CVS Health Ventures in its Series B investment round. The investment supports the scaling of Amalgam’s EHR-integrated clinical decision support platform to provide actionable information for health care providers (HCPs) for use at the point of care. Amalgam’s technology aligns and helps realize shared savings agreements between payers and HCPs. “Our i...

Amalgam Rx™ Enhances Partnership with Novo Nordisk®

WILMINGTON, Del.--(BUSINESS WIRE)--Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing the expansion of its global agreement with Novo Nordisk for the commercialization of Dose Check. The new agreement bolsters the existing partnership and product suite between Novo Nordisk and Amalgam by incorporating and integrating with connected insulin delivery devices, continuous glucose...

Amalgam Rx Named to the 2022 CB Insights’ Digital Health 150 List

NEW YORK--(BUSINESS WIRE)--CB Insights today named Amalgam Rx to its fourth-annual Digital Health 150, showcasing the 150 most promising private digital health companies of 2022. "From reimagining clinical care, to leveraging tech like AR/VR to improve surgical training, this year’s Digital Health 150 winners are transforming the future of healthcare with digital technology,” said Brian Lee, SVP of CB Insights’ Intelligence Unit. “This increasingly global cohort, representing more than 18 count...
Back to Newsroom